|
Russell, Heidi V; Strother, Douglas; Mei, Zhuyong et al. (2008) A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother 31:812-9
|
|
Russell, Heidi V; Strother, Douglas; Mei, Zhuyong et al. (2007) Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 30:227-33
|
|
Rousseau, Raphael F; Haight, Ann E; Hirschmann-Jax, Charlotte et al. (2003) Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 101:1718-26
|
|
Dotti, Gianpietro; Savoldo, Barbara; Yotnda, Patricia et al. (2002) Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. Blood 100:200-7
|
|
Rossig, C; Bollard, C M; Nuchtern, J G et al. (2001) Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 94:228-36
|
|
Takahashi, S; Rousseau, R F; Yotnda, P et al. (2001) Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther 12:659-70
|
|
Takahashi, S; Yotnda, P; Rousseau, R F et al. (2001) Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 8:378-87
|
|
Dotti, G; Savoldo, B; Takahashi, S et al. (2001) Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol 29:952-61
|
|
Roskrow, M A; Dilloo, D; Suzuki, N et al. (1999) Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res 23:549-57
|
